The U.S. Court of Appeals for the Third Circuit has let stand its August ruling upholding the dismissal of antitrust claims against GlaxoSmithKline.

The court denied petitions for both panel and en banc rehearings filed by direct and indirect purchasers of Wellbutrin XL.

The purchasers had alleged that a patent infringement settlement between GSK and generic drugmakers unlawfully delayed market entry of generic versions of the popular antidepressant.

Stephen J. Kastenberg and Leslie E. John, of Ballard Spahr in Philadelphia, argued the case for GSK.

Read the full article here. Subscription may be required.